未接受化疗的去势抵抗性前列腺癌男性的二线激素治疗:美国临床肿瘤学会临时临床意见
美国临床肿瘤学会发布临时临床意见,针对未接受化疗的去势抵抗性前列腺癌男性,从仅生化证据的无症状患者到有转移但症状轻微者,基于6项III期随机对照试验和专家共识,给出二线激素治疗、放射性核素和免疫治疗等推荐,并建议维持去势状态、监测PSA及影像学再分期。
要点
- 对于去势抵抗性前列腺癌男性,应无限期维持去势状态。
- 非转移性去势抵抗性前列腺癌且转移高风险者可考虑二线激素治疗,否则不建议。
- 有影像学转移且症状轻微者,应与患者讨论后提供恩扎卢胺或阿比特龙联合泼尼松。
核心结论
- 对于去势抵抗性前列腺癌男性,应无限期维持去势状态。
- 非转移性去势抵抗性前列腺癌且转移高风险(如前列腺特异性抗原倍增时间或速度较快)的患者可考虑二线激素治疗(如抗雄激素、CYP17抑制剂),否则不建议。
- 有影像学转移且症状轻微的患者,在与患者讨论潜在危害、获益、费用和患者偏好后,应提供恩扎卢胺或阿比特龙联合泼尼松。
- 镭-223和sipuleucel-T也是可选方案。
- 没有证据指导二线治疗之后激素治疗的最佳顺序。
研究设计与样本
- 美国临床肿瘤学会临时临床意见,基于6项III期随机对照试验和专家共识意见。
主要发现
- 6项III期随机对照试验和专家共识意见为本次临时临床意见提供依据。
关键数值与推荐
- 对于去势抵抗性前列腺癌男性,应无限期维持去势状态。
- 非转移性去势抵抗性前列腺癌且转移高风险(如前列腺特异性抗原倍增时间或速度较快)的患者可考虑二线激素治疗(如抗雄激素、CYP17抑制剂),否则不建议。
- 有影像学转移且症状轻微的患者,在与患者讨论潜在危害、获益、费用和患者偏好后,应提供恩扎卢胺或阿比特龙联合泼尼松。
- 镭-223和sipuleucel-T也是可选方案。
- 无转移患者每4至6个月检测前列腺特异性抗原是合理的。
临床怎么用
- 对于去势抵抗性前列腺癌男性,应无限期维持去势状态。
- 非转移性去势抵抗性前列腺癌且转移高风险的患者可考虑二线激素治疗,否则不建议。
- 有影像学转移且症状轻微的患者,在与患者讨论后应提供恩扎卢胺或阿比特龙联合泼尼松。
- 镭-223和sipuleucel-T也是可选方案。
- 无转移患者每4至6个月检测前列腺特异性抗原;常规影像学再分期通常不建议,但对有转移风险或出现症状或其他进展证据的患者可考虑。
局限性
- 没有证据提供关于去势抵抗性前列腺癌二线治疗之后激素治疗最佳顺序的指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership after publication or presentation of potential practice-changing data. This PCO addresses second-line hormonal therapy for chemotherapy-naïve men with castration-resistant prostate cancer (CRPC) who range from being asymptomatic with only biochemical evidence of CRPC to having documented metastases but minimal symptoms. Clinical Context The treatment goal for CRPC is palliation. Despite resistance to initial androgen deprivation therapy, most men respond to second-line hormonal therapies. However, guidelines have neither addressed second-line hormonal therapy for nonmetastatic CRPC nor provided specific guidance with regard to the chemotherapy-naïve population. Recent Data Six phase III randomized controlled trials and expert consensus opinion inform this PCO. Provisional Clinical Opinion For men with CRPC, a castrate state should be maintained indefinitely. Second-line hormonal therapy (eg, antiandrogens, CYP17 inhibitors) may be considered in patients with nonmetastatic CRPC at high risk for metastatic disease (rapid prostate-specific antigen doubling time or velocity) but otherwise is not suggested. In patients with radiographic evidence of metastases and minimal symptoms, enzalutamide or abiraterone plus prednisone should be offered after discussion with patients about potential harms, benefits, costs, and patient preferences. Radium-223 and sipuleucel-T also are options. No evidence provides guidance about the optimal order of hormonal therapies for CRPC beyond second-line treatment. Prostate-specific antigen testing every 4 to 6 months is reasonable for men without metastases. Routine radiographic restaging generally is not suggested but can be considered for patients at risk for metastases or who exhibit symptoms or other evidence of progression. Additional information is available at www.asco.org/genitourinary-cancer-guidelines and www.asco.org/guidelineswiki .
引用
- Virgo KS, Basch E, Loblaw DA, et al. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2017. PMID: 28441112. doi:10.1200/JCO.2017.72.8030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。